Jared Kelly
Fortune : 118 612 $ au 31/05/2026
Fortune : 118 612 $ au 31/05/2026
Jared Kelly is currently Chief Executive Officer & Director at Oncolytics Biotech, Inc. since 2025.
Mr. Kelly is also Secretary, Senior Vice President & General Counsel at Ambrx Biopharma Cayman, Inc. since 2023.
Formerly, Mr. Kelly was a Partner at Lowenstein Sandler LLP.
Mr. Kelly completed graduate studies at Georgetown University Law Center.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/06/2026 | 114 050 ( 0,1% ) | 118 612 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ONCOLYTICS BIOTECH INC. | Directeur Général | 11/06/2025 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biologics company | Conseiller Juridique Général | 13/09/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
Lowenstein Sandler LLP
Lowenstein Sandler LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Oncolytics Biotech, Inc.
Oncolytics Biotech, Inc. BiotechnologyHealth Technology Discovers and develops pharmaceutical products for the treatment of cancers | Health Technology |
Lowenstein Sandler LLP
Lowenstein Sandler LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Georgetown University Law Center
Georgetown University Law Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biologics company | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national